Nabriva Therapeutics Plc

NASDAQ:NBRV   3:59:43 PM EDT
1.37
-0.05 (-3.52%)
4:15:01 PM EDT: $1.51 +0.14 (+10.22%)
Products

Nabriva Therapeutics Granted New Technology Add-On Payment For Xenleta And Contepo

Published: 09/10/2020 13:43 GMT
Nabriva Therapeutics Plc (NBRV) - Nabriva Therapeutics Granted New Technology Add-on Payment for Xenleta® (lefamulin) and Contepo™ (fosfomycin) by Centers for Medicare & Medicaid Services.
Nabriva - From October 1, Cms to Give Additional Maximum Payment of $1,275.75 for Xenleta When Used in Inpatient Hospital Setting for Fiscal Year 2021.
Nabriva Therapeutics Plc - Iv and Oral Formulations of Xenleta Were Granted Qualified Infectious Disease Product and Fast Track Designation by FDA.